Alpine Immune Sciences, Inc. (NASDAQ:ALPN) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The revenue forecast for this year has experienced a facelift, with the analysts now much more optimistic on its sales pipeline.
Following the upgrade, the latest consensus from Alpine Immune Sciences' six analysts is for revenues of US$29m in 2021, which would reflect a sizeable 155% improvement in sales compared to the last 12 months. Losses are presumed to reduce, shrinking 13% from last year to US$1.31. Yet before this consensus update, the analysts had been forecasting revenues of US$29m and losses of US$1.30 per share in 2021. There doesn't appear to have been a major change in analyst sentiment following this consensus update, with minimal changes to revenue and loss per share estimates.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Alpine Immune Sciences' past performance and to peers in the same industry. It's clear from the latest estimates that Alpine Immune Sciences' rate of growth is expected to accelerate meaningfully, with the forecast 249% annualised revenue growth to the end of 2021 noticeably faster than its historical growth of 97% p.a. over the past three years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 13% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Alpine Immune Sciences is expected to grow much faster than its industry.
The Bottom Line
The most important thing here is that analysts reduced their loss per share estimates for this year, reflecting increased optimism around Alpine Immune Sciences' prospects. On the plus side, there were no major changes to revenue estimates; although analyst forecasts do imply revenues will come in ahead of the wider market. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at Alpine Immune Sciences.
Analysts are clearly in love with Alpine Immune Sciences at the moment, but before diving in - you should be aware that we've identified some warning flags with the business, such as dilutive stock issuance over the past year. For more information, you can click through to our platform to learn more about this and the 3 other concerns we've identified .
Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.